The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol

• Published in: British journal of haematology 2022-03, Vol.196 (5), p.1257-1261
• Main Authors: Moriya, Kunihiko, Imamura, Toshihiko, Katayama, Saori, Kaino, Akira, Okamoto, Kenji, Yokoyama, Norihumi, Uemura, Suguru, Kitazawa, Hironobu, Sekimizu, Masahiro, Hiramatsu, Hidefumi, Usami, Ikuya, Ishida, Hisashi, Hasegawa, Daiichiro, Hama, Asahito, Moriya‐Saito, Akiko, Sato, Atsushi, Sasahara, Yoji, Suenobu, Souichi, Horibe, Keizo, Hara, Junichi
• Format: Article
• Language: English
• Subjects: acute lymphoblastic leukaemia; Acute lymphoblastic leukemia; Adolescent; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asparaginase - adverse effects; Asparaginase - therapeutic use; Berlin‐Frankfurt‐Münster (BFM)95‐based protocol; Child; Child, Preschool; Children; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Cytarabine - adverse effects; Cytarabine - therapeutic use; Daunorubicin - adverse effects; Daunorubicin - therapeutic use; Female; Hematology; Humans; Incidence; Infant; Japan - epidemiology; Japanese children; Leukemia; Male; Mercaptopurine - adverse effects; Mercaptopurine - therapeutic use; Osteonecrosis; Osteonecrosis - chemically induced; Pediatrics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology; Prednisolone - adverse effects; Prednisolone - therapeutic use; Prednisone - adverse effects; Prednisone - therapeutic use; Retrospective Studies; Risk factors; Vincristine - adverse effects; Vincristine - therapeutic use
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.17988

Summary In this study, we performed a retrospective analysis of a cohort of Japanese paediatric patients with B‐cell precursor (BCP)‐acute lymphoblastic leukaemia (ALL) treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol, to clarify the incidence, clinical characteristics, and risk factors of osteonecrosis (ON) in comparison to the ALL‐02 protocol. We identified a high frequency of ON with the BFM95‐based protocol compared to the ALL‐02 protocol. The incidence of symptomatic ON with the BFM95‐based protocol is comparable to previous studies in Western countries. We believe that the type of treatment regimen has more impact on the incidence of symptomatic ON in paediatric ALL than ethnicity.